Vaccine Contract Manufacturing Market Size, Share, Demand & Trends Analysis Report by 2032

Vaccine Contract Manufacturing Market Insights

Zion Market Research has published a report on the global Vaccine Contract Manufacturing Market, estimating its value at USD 6.19 Billion in 2023, with projections indicating that it will reach USD 17.25 Billion by 2032. The market is expected to expand at a compound annual growth rate (CAGR) of 10.8% over the forecast period 2024-2032. The report explores the factors fueling market growth, the hitches that could hamper this expansion, and the opportunities that may arise in the Vaccine Contract Manufacturing Market industry. Additionally, it offers a detailed analysis of how these elements will affect market demand dynamics and market performance throughout the forecast period.

Request Free Sample

The report offers assessment and analysis of the Vaccine Contract Manufacturing market on a global and regional level. The study offers a comprehensive assessment of the market competition, constraints, revenue estimates, opportunities, evolving trends, and industry-validated data. The report provides historical data from 2018 to 2022 along with a forecast from 2024 to 2032 based on revenue USD Billion.

Vaccine Contract Manufacturing Market: Overview

Vaccine manufacturing sector is one among the challenging ones with the basic manufacturing steps being the most difficult to get executed in a safe & proficient manner. With thriving vaccine sector, both vaccine manufacturing industry as well as vaccine contract manufacturing market is likely to thrive over the coming decade. According to NCBI, overall vaccine sales in 2013 were over USD 24 billion and are slated to increase noticeably in the upcoming years. This will pave a way for exponential expansion of vaccine industry as well as vaccine contract manufacturing business over the years to come.  

Request Free Sample

Vaccine Contract Manufacturing Market: Growth Factors

As per NCBI, presence of giant vaccine manufacturing firms based in the U.S. and Europe as well as new entrants evolving in the developing countries, the market for vaccine contract manufacturing is set to expand leaps & bounds in the years ahead. In addition to this, the need for reducing spread of COVID across the globe has forced governments to focus on manufacturing vaccines. This has led to massive growth of vaccine manufacturing business along with boosting vaccine contract manufacturing industry over 2024 – 2032.

Furthermore, large-scale demand for vaccines in emerging countries as well as under-developed countries will enlarge the scope of vaccine contract manufacturing industry over the assessment timeframe. Large-scale funding on research activities concerning vaccine production and need for maintaining the demand-supply equilibrium has influenced vaccine contract manufacturing market penetration. Furthermore, giant firms are entering into partnership with regional firms form expanding their customer base across the globe, thereby further impacting the expansion of the market.

Apart from this, introduction of new products to the existing product line witnessed in the developed countries is likely to lead to expansion of vaccine contract manufacturing activities in the emerging economies, thereby inflating market size in these countries over the assessment timeline. However, with giant pharma firms across the globe adopting the strategy of producing vaccines in-house, the growth of vaccine contract manufacturing industry may witness a rapid decline & market revenue may be hit severely by the execution of this strategy in the years to come.

Vaccine Contract Manufacturing Market: Report Scope

Vaccine Contract Manufacturing Market: Regional Landscape

North American Market Share To Increase Sizably Over Forecast Period

The expansion of vaccine contract manufacturing market in North America over the assessment timespan is due to large-scale presence of bio-pharma firms in the U.S. In addition to this, legislations supporting the vaccine contract manufacturing activities in the sub-continent will add substantially to the GDP of the region due to surge in the vaccine contract manufacturing business, thereby providing impetus to the vaccine contract manufacturing industry in North America. Apart from this, a prominent increment in the contract research firms aided by both the government as well as funding from private sector will culminate in steep escalation of the market size in the sub-continent over 2024 – 2032.

Vaccine Contract Manufacturing Market: Competitive Landscape

Some of the leading players in the global market inlcude

• Goodwin Biotechnology Inc.
• Minneapolis Medical Research Foundation (MMRF)
• Soligenix Inc.
• FUJIFILM Diosynth Biotechnologies
• Thomas Jefferson University
• Bavarian Nordic A/S
• Emergent BioSolutions
• BioMark
• Catalent Biologics.

The global Vaccine Contract Manufacturing Market is segmented as follows:

By Vaccine Type

• Attenuated
• Subunit
• DNA
• Inactivated
• Toxoid

By Workflow

• Downstream
• Upstream

By Application

• Human
• Veterinary

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa